When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 2.9x, you may consider Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) as a stock to avoid entirely with its 10.8x P/S ratio. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.
SZSE:000766 Price to Sales Ratio vs Industry July 12th 2024
What Does Tonghua Golden-Horse Pharmaceutical Industry CoLtd's P/S Mean For Shareholders?
It looks like revenue growth has deserted Tonghua Golden-Horse Pharmaceutical Industry CoLtd recently, which is not something to boast about. One possibility is that the P/S is high because investors think the benign revenue growth will improve to outperform the broader industry in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Tonghua Golden-Horse Pharmaceutical Industry CoLtd's earnings, revenue and cash flow.
Is There Enough Revenue Growth Forecasted For Tonghua Golden-Horse Pharmaceutical Industry CoLtd?
Tonghua Golden-Horse Pharmaceutical Industry CoLtd's P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.
Taking a look back first, we see that there was hardly any revenue growth to speak of for the company over the past year. Although pleasingly revenue has lifted 33% in aggregate from three years ago, notwithstanding the last 12 months. Therefore, it's fair to say the revenue growth recently has been great for the company, but investors will want to ask why it has slowed to such an extent.
Comparing that to the industry, which is predicted to deliver 18% growth in the next 12 months, the company's momentum is weaker, based on recent medium-term annualised revenue results.
In light of this, it's alarming that Tonghua Golden-Horse Pharmaceutical Industry CoLtd's P/S sits above the majority of other companies. It seems most investors are ignoring the fairly limited recent growth rates and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent revenue trends is likely to weigh heavily on the share price eventually.
The Key Takeaway
Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
Our examination of Tonghua Golden-Horse Pharmaceutical Industry CoLtd revealed its poor three-year revenue trends aren't detracting from the P/S as much as we though, given they look worse than current industry expectations. Right now we aren't comfortable with the high P/S as this revenue performance isn't likely to support such positive sentiment for long. Unless there is a significant improvement in the company's medium-term performance, it will be difficult to prevent the P/S ratio from declining to a more reasonable level.
You always need to take note of risks, for example - Tonghua Golden-Horse Pharmaceutical Industry CoLtd has 1 warning sign we think you should be aware of.
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
